Orifarm strengthens executive team with two new leadership appointments

Orifarm Group A/S ("Orifarm"), is pleased to announce that the strategic investment with Carlyle Global Credit (NASDAQ: CG) has successfully closed following approval from relevant regulatory authorities. Orifarm is a dynamic, family-owned, international healthcare company, supplying high quality pharmaceuticals at affordable prices through a unique commercial platform covering three business areas: Pharma Trade, Specialty Rx and Consumer Healthcare. This strategic investment, as announced on 13 September 2024, will look to strengthen Orifarm’s ongoing expansion, both organic and inorganic, building on its strong pan-European presence, and expand its coverage of accessible, high-quality, and affordable medicines. "This capital infusion will significantly enhance our ability to capitalize on the attractive opportunities, both organic and inorganic, that we have positioned Orifarm for. We are delighted to have Carlyle as a strategic capital partner to support this next chapter of Orifarm’s growth,” said Erik Sandberg, CEO of Orifarm Group. Orifarm was founded in 1994 by Hans and Birgitte Bøgh-Sørensen and will remain privately owned by the family following this transaction. The terms of the transaction are confidential. Rothschild & Co acted as the sole financial advisor to Orifarm and owners, Habico, together with the owners’ dedicated family office, Habico Invest. Kromann Reumert was legal advisor to Orifarm and Habico.   Related news: 13 September 2024: Orifarm Group Announces Strategic Investment from Carlyle Global Credit   About Orifarm Group A/SOrifarm is a dynamic family-owned international healthcare company supplying high-quality pharmaceuticals at affordable prices through a unique commercial platform covering three business areas: Pharma Trade, Specialty Rx, and Consumer Healthcare. Headquartered in Odense, Denmark, Orifarm is Europe's largest parallel importer of pharmaceuticals and Denmark's largest supplier of pharmaceuticals, with 2,300 employees in 16 countries and an annual turnover of more than €1.5 billion (2023).   About Carlyle Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Global Investment Solutions. With $435 billion of assets under management as of June 30, 2024, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,200 people in 29 offices across four continents. Further information is available at www.carlyle.com.   For further information, please contact: Kristian Lysgaard, VP of Communications, Orifarm Group A/SEmail: krlys@orifarm.comPhone: +45 25 56 85 61

The official inauguration of the new office for Orifarm's Swedish subsidiary, located in the heart of Stockholm, was celebrated with a memorable event. The afternoon featured the presence of prominent visitors, which beyond the owners Birgitte and Hans Bøgh-Sørensen, CEO Erik Sandberg, CPO Andreas Friis, and CFO Mads Find Eriksen. The highlight of the event was the official ribbon-cutting ceremony, performed by Birgitte Bøgh-Sørensen, who played a significant role in the office's design. The celebration included toasts with sparkling beverages and a selection of macaroons and cupcakes in Orifarm's colors.General Manager of Orifarm Sweden Christian Vallentin and his team presented the latest success stories from Sweden, followed by a celebration of an all-time high in October sales, marking a significant achievement for the Swedish team. Perfect timing to celebrate at the inauguration!  CEO Erik Sandberg delivered an inspiring speech to the team, and Owner and Chairman Hans Bøgh-Sørensen provided a historical overview of the Swedish business from its inception to the present day. The speeches and presentations were well-received by all attendees. “It was really a joyful celebration and at the same time inspiring event with Hans and Birgitte, and several EMG members visiting us at the same time. We have really accomplished new huge milestones for Orifarm SE last years, with profitable growth in all business areas and a more mature local organization that is truly based on 3 business platforms. We are also indeed very excited and pleased to have move into our new Orifarm themed modern and more spacious office in really the center of Stockholm, where we look forward to host many more important events.” says Christian Vallentin.       The event marked a significant milestone for Orifarm in Sweden, setting the stage for continued success in the new office space. 

Consumers in Denmark have Europe’s most affordable supply of generic medicines in 2024, the Danish Pharmacy Association’s annual record show. Every year, the Danish Pharmacy Association (Danmarks Apotekerforening) announces statistic and analyses from the year just passed. Having published findings from 2024 conducted by the international market research institute Iqvia, figures show that Danish consumers have access to the most affordable generics medicines in all of Europe. “Generic medicines are alternatives to brand-name prescription drugs and play an important role when it comes to ensuring access to health in the general society, as they are available at far more affordable costs,” explains Karsten Haumann, responsible for sales in Denmark at Orifarm. In Denmark, generic medicines make up 75% of all medicines sold at pharmacies, according to the Danish Pharmacy Association. Generic medicines play an important role when it comes to ensuring access to health in the general society, as they are available at far more affordable costs, explains Karsten Haumann, responsible for sales in Denmark at Orifarm.   Danish framework conditions lay ground for affordable prices Danish consumers having access to affordable medicines can largely be attributed good framework conditions for the pharmaceutical industry. These conditions include the biweekly tariff system – referred to as “Taksten” in Danish. In the biweekly tariff, pharmaceutical companies bid on winning the supply of medicines for a two-week period. The winning supplier also commits to supplying the market for the full two weeks. The system thereby keeps security of supply high, while also creating competition between suppliers, ultimately benefiting the patients needing care. Also, by law, pharmacies must offer the cheapest alternative. As a patient you can always request a different brand, but the pharmacy must inform you of the cheaper alternative. “To maintain the low prices in Denmark, we must uphold these legislative requirements and tools. Framework conditions have direct impact on patients, and on our society that offers reimbursements of many medical expenses,” says Karsten Haumann. Adding to keeping prices at affordable level for patients is the pharmacies’ possibility for substitution. When prescribing medicine, doctors often automatically prescribe an original medication. With the possibility of substitution, pharmacists can offer a generic alternative to the prescription, meaning that they offer the patient a more affordable, yet identical, product. In 2023, pharmacies substituted prescribed medicines to cheaper alternatives more than 21 million times. Strictly regulated medicines Generic pharmaceuticals are subject to the same strict regulation and high-quality standards as the original products. The active ingredient in a generic product is identical to the active ingredient in the original product. You can dive into how we work to ensure high quality for these healthcare brands here.    Generic medicines are alternatives to brand-name prescription drugs and are offered when the originators' patent expires. What is Generic Medicine? Generic medicines, also known as Generics, are affordable and accessible alternatives to brand-name prescription drugs, offering patients the needed treatment at much lower cost without compromising on quality or safety. When a patent for an original prescription pharmaceutical expires, we have the opportunity of marketing generic variants of the original brand-name product that hold the same Active Pharmaceutical Ingredient. Generics have the same Active Ingredients as the original medicine, live up to the same standards for quality and safety, promote affordability and availability, and make interchangeability easier for the healthcare professionals prescribing medicines. All generic products undergo strict testing and adhere to the same quality and safety requirements set by the health authorities as the original manufacturer.

Orifarm Group A/S has announced that the Global Credit platform of the global investment firm Carlyle (NASDAQ:CG) has agreed to commit strategic capital to Orifarm to support its future growth. Subject to relevant regulatory approvals, the transaction is expected to close in Q4 2024. Orifarm is a dynamic, family-owned, international healthcare company, supplying high quality pharmaceuticals at affordable prices through a unique commercial platform covering three business areas: Pharma Trade, Specialty Rx and Consumer Healthcare. Orifarm was founded in 1994 by Hans and Birgitte Bøgh-Sørensen and will remain privately owned by the family following this transaction. This strategic investment will look to strengthen Orifarm’s ongoing expansion, both organic and inorganic, building on its strong pan-European presence, and expand its coverage of accessible, high-quality, and affordable medicines. Hans Bøgh-Sørensen, Chairman and founder of Orifarm, commented: “Since founding Orifarm over 30 years ago, the drive for continuous growth and development has been the cornerstone of our success. As a family and multi-generational owner, it is essential that Orifarm retains the financial flexibility to continue pursuing its growth ambitions while delivering on its purpose of supplying affordable medicines and remaining true to its heritage and the Orifarm way of doing business. We are delighted to partner with Carlyle’s credit business to support the next chapter of Orifarm’s growth.” Erik Sandberg, CEO of Orifarm Group, said: “This strategic investment will significantly enhance our ability to capitalise on the attractive opportunities, both organic and inorganic, that we positioned Orifarm for following the transformational asset deal with Takeda in 2020. We are confident that this marks the start of an exciting future for the business, our employees, and other stakeholders.” Nicola Falcinelli, Deputy Head of European Private Credit at Carlyle, said: “We are delighted to support Orifarm, a multi-generational founder-owned business with a dedicated focus on product quality, affordability and accessibility. This transaction underlines our ability to provide tailored capital solutions to established, family-owned businesses in order to accelerate their growth trajectory.” The terms of the transaction are confidential. Rothschild & Co acted as the sole financial advisor to Orifarm and owners, Habico, together with the owners’ dedicated family office, Habico Invest. Kromann Reumert was legal advisor to Orifarm and Habico.   About Orifarm Orifarm is a dynamic, family-owned, international healthcare company, supplying high quality pharmaceuticals at affordable prices through a unique commercial platform covering three business areas: Pharma Trade, Specialty Rx and Consumer Healthcare. Orifarm was founded in 1994 by Hans and Birgitte Bøgh-Sørensen. Orifarm Group, headquartered in Odense, Denmark, is Europe's largest parallel importer of pharmaceuticals and Denmark's largest supplier of pharmaceuticals. It is one of the largest Danish pharmaceutical companies with 2,300 employees in 16 countries and with an annual turnover of more than €1.5 billion.   About Carlyle Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $435 billion of assets under management as of June 30, 2024, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,200 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

Today, Orifarm Group announces that Mads Fink Eriksen will join the Group on 1 October 2024 as the Chief Financial Officer.   Mads comes from a similar position in Ecco and brings extensive experience within end-to-end processes from roles held in production and procurement as well as in sales. Mads has significant international experience from a career that spans leadership positions in China, India, Singapore and Australia. He holds a Bachelor in Business Administration from Aarhus University and an Executive MBA from INSEAD.    “I am looking forward to welcoming Mads to Orifarm. I am sure we will benefit of his experience and strong strategic mindset when growing Orifarm in the future,” says CEO Erik Sandberg.   “Orifarm has an ambitious and inspiring future strategy, which I look forward to helping to fulfill. I hope to bring some new perspectives to the daily work and, not least, to get to know all the talented employees at Orifarm,” says Mads Fink Eriksen.   Mads succeeds Jacob Berg Lucassen who will leave Orifarm after mutual agreement. Jacob has been with Orifarm for 17 years and has played an incremental role in building our Finance set-up to where it is today.    “I would like to express our gratitude for Jacob’s relentless efforts in improving our Financial set up, which has seen significant enhancement over the past years, and in general for his significant and very loyal contribution to Orifarm. We wish Jacob all the best in his future endeavors,” says CEO Erik Sandberg.  For further information please contact Orifarm’s Corporate Communications. 

At Orifarm, Student Assistant like Frederik Krabbe Jepsen receive more than just a paycheck - they also have a share of the company's profits on equal terms with all other employees. The bonus is part of Orifarm's inclusive culture, reflecting its commitment to valuing every employee.   For Frederik, a master’s student in Business, Language, and Culture (Negot) at the University of Southern Denmark (SDU), being included in the bonus scheme is part of a through-going view on Student Assistants as equals who are trusted with own responsibilities: “I enjoy that Student Assistants receive equal treatment to other employees. We’re actively included in decision-making processes related to our tasks and are entrusted with completing and delivering our own assignments. This approach contributes to our experience in learning the ways of functioning in a workplace. Being included in the bonus scheme is of course also a great recognition of our work, and something I highly appreciate,” says 26-year old Frederik Krabbe Jepsen. Frederik is completing his master’s degree while working in Orifarm’s Parallel Imports Procurement department. His responsibilities range from handling invoices and cross-referencing them with the correct prices to assisting the Hospital Sales department in bidding on tenders for hospitals. “For me, it is essential to learn how to ‘go to work’. My studies serve as a foundation, but at Orifarm I develop and strengthen the competencies necessary for my future career,” says Frederik Krabbe Jepsen.     Inclusivity and shared success Orifarm’s Chief People Officer, Andreas Friis, explains the company’s philosophy: "Our culture is about inclusivity and shared success. Student Assistants contribute to our results, so of course they are also rewarded in our common bonus scheme on equal terms as all other employees. At Orifarm, bonusses are based on our shared overall success, not on individual performance." Andreas Friis also highlights the mutual benefits of employing student workers. "They bring fresh knowledge and diverse perspectives from their studies, enriching our workforce. At the same time, they gain valuable practical experience, which makes them stronger candidates post-graduation. Many choose to stay with us after completing their studies." Orifarm’s inclusive bonus scheme and supportive work environment make it an attractive place for Student Assistants to develop their careers, benefiting both the company and its young talent.

"Responsibility and a learning-friendly environment," echoes Student Assistants Sarah Bedford and Frederik Krabbe Jepsen when asked what comes to mind when they think of Orifarm. Across our organization, Orifarm employs more than 60 Student Assistants, contributing with fresh perspectives and providing valuable support across our organization. Beyond assisting with tasks, students gain practical work experience, develop professional skills, and make connections. In return, they contribute with curiosity and open-mindedness. Frederik, who works in Procurement and studies Business, Language, and Culture, highlights the fact that students are treated like other employees: “I enjoy that Student Assistants receive the same treatment as other employees. For instance, we are part of Orifarm’s employee bonus scheme just like everyone else. We’re also actively included in decision-making processes, and our colleagues trust that we deliver on our own tasks. This approach helps us learn ‘how to go to work’,” he says. Sarah, who studies Biomedicine and works in Regulatory Affairs, appreciates that her job is flexible and aligns with her studies: “Regarding work schedules and remote work, we enjoy equal flexibility as other employees. This allows us to balance work and studies even on a tight schedule and fosters a sense of respect and trust,” says Sarah Bedford and continues: “Most of my tasks are related to my studies. Traditionally, Biomedicine students end up in research, but I can’t see myself as a researcher. Here at Orifarm, I get to use my knowledge in a different way, and that’s exciting,” says Sarah Bedford. It is safe to say that Student Assistants are great assets to Orifarm, and we are proud of all the young minds contributing to our mission of creating healthy days for all.

Orifarm employs several nurses. One of them is Camille Løve Andersen, who works as a Change Management Specialist in our Corporate People & Culture.  Camille’s background as a nurse hasn't just been a steppingstone but an indispensable resource in her current role at Orifarm, where she leverages both her professional expertise and human empathy to steer change management processes.   As a nurse, Camille has cultivated the ability to analyze situations with both a critical eye and a heart that understands the human aspect. This blend of analytical skills and empathetic insight is a gift, especially when faced with new and challenging situations where the need for change is urgent or demanding.  We’re proud to employ nurses like Camille who not only care but also lead and inspire change.

In spring, Orifarm's Data Community gathered for its 5th landmark event, a testament to Orifarm’s commitment to staying at the forefront of AI and machine learning innovation.   The event, attended physically and virtually by Orifarm employees across locations, served as a vibrant platform for unveiling the complex world of AI and Machine Learning and showcasing AI’s many abilities.  The Data Community Event is a quarterly initiative which started 2 years ago, engaging Orifarm employees working with data or interested in data. At its start 20 data enthusiasts were involved – a number that has since grown to over 120 participants.  Naturally so, a recurring theme of the event was the anticipation surrounding OriChat – Orifarm’s very own conversational genAI tool soon launched throughout the organization. The excitement led to a number of questions and discussions about the future capabilities and applications of OriChat within Orifarm. Given the interest, Orifarm is already planning the next stage of this initiative, promising to delve deeper into the practical applications of genAI. 

As Orifarm grows to make healthcare accessible to as many as possible, so does cross-border collaboration and engagement in all parts of our company.   Recognizing the importance of effective communication in our multinational environment, where English serves as our corporate language, we have initiated a 12-week course for interested warehouse colleagues in Denmark. This course, comprising 12 sessions of 3 hours each, aims to equip our warehouse team with the necessary language skills to excel in their roles, serving Orifarm locations all over Europe.   The enthusiasm among our employees is evident and all participants are eager to master skills such as writing and reading emails in English and engaging in job-relevant conversations.  Here's to embracing new learnings.

Orifarm steps into the future of workplace innovation with the launch of our very own Artificial Intelligence tools.  Our new Orifarm Generative AI tools are set to revolutionize the way we work, empowering all Orifarm colleagues with support and efficiency in day-to-day tasks. The tools are designed to assist colleagues regardless of function, boosting productivity and freeing up valuable time for creativity and strategic thinking. Looking for opportunity has always been deeply rooted in the Orifarm DNA.  By embarking on the journey into the future of work with our own AI tools, we limit the risk of data leaks to outside parties; as with everything we do, we are committed to ensuring the highest level of safety. 

We’re really proud to announce that mbrace menopause has won a Danish Beauty Award!  The Danish Beauty Awards was held on 19 April in Copenhagen, Denmark, and mbrace won in the Inner Wellbeing Category. mbrace is a series of food supplements designed for women in menopause. Menopause is a natural part of aging, yet still met by many myths and misunderstandings, and there’s generally a lack of information to women experiencing menopause. We hope to improve focus on menopause, so that we all understand what the period may entail and be better equipped to respond to the changes. With the three products in the series, we want to let women know that these changes can be managed to keep living life to its fullest.   For more information about mbrace, please visit https://orifarmhealth.dk/brands/mbrace

After relocating his family to Orifarm Norway in Oslo, Robin Lorvik learned valuable lessons navigating cultural differences and enhancing business interactions in Norway. Reflecting on notable aspects of his transition to Norway, Robin emphasizes navigating cultural differences:   “Compared to Denmark, Norwegians tend to be more humble and less direct, which has required me to adjust my communication style. Consulting with colleagues has been pivotal in refining our approach and strengthening relationships with our customers. So, although Denmark and Norway share many similarities, there are small differences as well,” says Robin Lorvik.  Throughout his time in Orifarm Norway, Robin has achieved significant milestones, including succesfully implementing Nycoplus floor displays in 465 pharmacies and leading various projects aiming to enhance visibility and customer navigation to provide healthier days for as many as possible.  “While adapting to life in Norway has presented challenges, embracing local activities like joining a football club has enriched my personal experience. Overall, I'm grateful for the opportunities and satisfaction this move has brought both personally and professionally, “Robin concludes. 

From stepping into Orifarm as a Student Assistant to now being the youngest manager in Norway, Thea Henie Tinderholt's time in Orifarm has been nothing short of transformative.  “In many ways, I’ve grown alongside Orifarm,” Thea Henie Tinderholt starts, when asked about her journey as part of Orifarm Norway.  Beginning her career at Orifarm in 2016, Thea initially dived into parallel imports and product research. Upon completing her studies in Administration and Management, she was offered a permanent role as Portfolio Coordinator for generics medicine and parallel imports.  From starting with a smaller portfolio and being part of a very small team in Norway during her student days to now being a team of 18 with a diverse and expansive portfolio, both Orifarm and Thea have flourished over the years. “I ended up in Orifarm almost by coincidence during my first year of university. Luckily so! It has been an exciting journey that has led me to my current role with responsibility for a large and quite broad portfolio,” says Thea Henie Tinderholt who continues:  “It's been an exciting adventure, and I'm eager to continue embracing new challenges and opportunities that lie ahead.”  We’re thrilled to be part of the professional development of young talents like Thea. Here’s to inspiring the next generation of female leaders!

Following a satisfactory 2023, resulting in another record for both revenue and operating profit, Orifarm now prepares for further growth.  Highlights from the 2023 accounts: Revenue increased by 3.6% to €1.567,7 million, which is a new record for Orifarm.  The Pharma Trade unit, which among others includes parallel import of pharmaceuticals, sets a new revenue record for the seventh consecutive year.  The gross profit increased by 16.3% to €268.3 million, while the operating profit increased by 29% to €76.0 million.    2023 was characterized by optimizing internal processes as part of the integration process after acquiring over 100 products and two production sites from Takeda in 2020.  The high level of investments from the year before was maintained, meaning that Orifarm collectively has spent €90.8 million on improvements over the past four years.  The number of employees increased by 5% compared to the previous year to a total of 2,242 employees (average number of full-time employees)  Orifarm, one of Europe’s largest parallel importers of pharmaceuticals, Revenue increased by almost 4% to €1.567,7 million, which is the highest revenue yet in the family-owned business headquartered in Denmark, shows the company’s financial statement for 2023 released today along with the company’s ESG report. The operating profit increased by a staggering 29% to yet another record of €76.0 million. The result is achieved despite Orifarm in 2023 spending €28.0 million on restructuring and integration following the acquisition of products and production sites from Takeda in 2020 as well as expenses covering the closing of the impacted negatively from low currency rates in Sweden and Norway. However, only deeming the financial statement satisfactory is due to the annual profit after financial items decreasing by approximately 13% to €22.4 million. This is caused mainly by a significant increase in interest payments impacted by increasing inflation and the high interest rates derived. “2023 was characterized by a focused effort to serve our customers and patients while implementing internal improvements. We addressed the supply chain issues stemming from the acquisition in 2020, while also further optimizing and professionalizing our business,” says CEO of Orifarm, Erik Sandberg, commenting on the financial statement. Record revenue for the seventh consecutive year “I am particularly pleased that our parallel imports business has set another record for both revenue and gross profit for the seventh consecutive year. It is a fantastic result in a market with increased competition and price pressure. At the same time, our generic pharmaceuticals show progress after a period with supply issues following the acquisition of more than 100 products and two production sites in 2020. Those issues are now solved, and the coming years look promising,” says Erik Sandberg.   During 2023, Orifarm has invested more than €25.6 million in improving the company’s processes and systems as well as inaugurating a new building at its headquarters in Denmark, which houses approximately 700 of the company’s nearly 2,300 employees.  Collectively, Orifarm has invested more than €90.8 million in improvements preparing the company for further growth in the coming years. 2024 expectations For 2024, Orifarm expects its revenue to grow by up to 10%, while the operating profit is expected to increase by between 5 and 15%. Growth is to occur organically as well as through acquisitions. “Orifarm is in a good position focusing on further growth in a market permeated by tough price competition. We have a strong platform in the Nordics, where we want to strengthen our portfolio and the strong product brands, we acquired in 2020 further. We also see potential in our German business, which year after year performs very well, with room for further growth,” says Erik Sandberg about the expectations for 2024. Additional information  For additional information, please contact VP Corporate Communications in Orifarm, Kristian Lysgaard, on +45 2556 8561 or krlys@orifarm.com.   

Following the successful integration of assets and people from Takeda, Orifarm will now simplify the business model. “Since the acquisition of the Takeda assets almost three years ago, Orifarm has changed quite significantly. We have integrated new businesses, we expanded into new geographies, and we welcomed many new colleagues. The combined effort of everyone in Orifarm has taken us far, and today we have a strong platform for continuous growth,” says CEO Erik Sandberg. A significant change will be the merger of the two business areas, Health Access and Healthcare, as they will be combined into one business area. “In order to sharpen our profile and offering towards our customers will we merge our two commercial business units into one, ensuring that we face the customers as one unified commercial organization,” says Erik Sandberg. To match the new commercial set up, Orifarm has decided to combine supply chains into one business unit covering sourcing and supply chain. Finally, Orifarm will adjust the rest of the organization to match the commercial setup and ensure efficient processes and an agile organization ready to respond to customer’s need. “With this restructuring we would like to prepare Orifarm for future growth by ensuring one face to the customer and operating in a more agile and lean organization,” says Erik Sandberg. Changes to the Executive Management Group As a consequence of the new organizational structure, a few changes to the Executive Management Group have been implemented. The combined commercial business unit will be headed by Thomas Brandhof, who will assume the role as Chief Commercial Officer, responsible for the entire portfolio and markets. Thomas was previously Chief Commercial Officer in Orifarm´s Health Access business unit.. Thomas Hedegaard has been promoted and will assume the position as Chief Sourcing Officer. Thomas was previously Vice President of Procurement in Orifarm’s Health Access business unit. The role as Chief Sourcing Officer is new in Orifarm, and Thomas will play a vital role in leading and developing an end-to-end supply chain, covering both the former Health Access and Healthcare business units.  There will be no changes to support functions, except that Corporate Communications will move to Global People & Culture headed by Chief People Officer, Andreas Friis. Consequently, VP, Corporate Communication Kristian Lysgaard steps out of EMG. Unfortunately, the changes also mean that Chief Commercial Officer, Orifarm Healthcare, Dennis Dencher, will leave Orifarm as his position is terminated. “It is with regret, we have to say goodbye to Dennis. He has been deeply involved in integrating the assets we acquired from Takeda, including welcoming more than 600 people and ensuring a successful integration. Dennis can be immensely proud of his significant contribution, and I wish him all the best going forward,” says CEO Erik Sandberg. The new Executive Management Group Chief Executive Officer Erik Sandberg Chief Financial Officer Jacob Berg Lucassen Chief Commercial Officer Thomas Brandhof Chief Sourcing Officer Thomas Hedegaard Chief People Officer Andreas Friis Chief Information Officer Klaus Mortensen Chief Corporate Compliance Officer Birgitte Røddik Corporate Development Officer Ulrik Markussen

This weekend football talents from Denmark and abroad come together when the Christian Eriksen Cup kicks off just minutes from Orifarm’s headquarter.  “At Orifarm, we work every day to create healthy days for as many people as possible. As a National Partner, we have the opportunity to work toward that goal beyond Pharma. By promoting youth communities centered around sports, we support not only football talents but also an active community that fosters joy and health,” says Erik Sandberg, CEO at Orifarm.  Read the full announcement here: https://lnkd.in/dDb5Jvs5 

Orifarm is proud to sponsor Sport’n’Charity – an organization helping children affected by cancer by offering physical activity known to improve the children's health in this vulnerable time. Orifarm is proud to sponsor Sport’n’Charity who helps children affected by cancer by offering individual training programs suitable to the course of their illness.  Scientific research shows that children and youth affected by cancer who are physically active during and after their cancer treatments can limit the risk of complications, illnesses, and disabilities. Sport’n’Charity is a cause truly close to our hearts in Orifarm. We are united in one, simple purpose: for as many as possible, as healthy a day as possible. “Orifarm exists to bring healthy days to as many as possible. Sport’n’Charity is about just that. Recognizing that we all have different challenges and possibilities, we are more than happy to support the work done by this fantastic organization to enable as healthy a day as possible for children that are fighting to overcome physical challenges second to none. These children are incredible, and we are genuinely proud to support them on this tough journey,” says Erik Sandberg, CEO of Orifarm. In collaboration with physiotherapists and training specialists, a training program is developed individually for every child. This means that the activities are tailored to the child’s course of illness; some train at home and some while in hospital. Research further shows that children affected by cancer who are physically active with others are more motivated to complete the training and do so for a longer period of time, which is why also their families and friends are welcome to join the training program. You can learn more about Sport’n’Charity here (information in Danish): www.sportncharity.dk

Danish pharma company Orifarm, leading in parallel import in the EU and owner of numerous healthcare brands, announces its recent appointment of Birgitte Røddik as new Chief Corporate Compliance Officer. Birgitte Røddik takes on the role of Chief Corporate Compliance Officer in Danish pharma company Orifarm. Holding a Master’s in Science and having held positions in Medtronic and Novo Nordisk, Birgitte Røddik brings valuable insights from the pharmaceutical industry. “I am very happy to welcome Birgitte Røddik to the Orifarm team. Birgitte Røddik joins us with comprehensive experience from the industry, combining the quality function with operational planning and commercial outlook. With this insight, she is to ensure that our high-quality mindset persists throughout our organization, making sure that the quality of Orifarm products is maintained from manufacturer to supplier to end-user. Patient safety is our top priority,” says CEO of Orifarm, Erik Sandberg. With more than 25 years' experience in developing and executing strategy into viable implementation plans and operating models and combining these with quality, regulatory affairs, and operations excellence, Birgitte Røddik seeks to further develop the important compliance function at Orifarm: “Orifarm plays a substantial role in society when it comes to making medicine accessible at affordable costs. I look forward to continuing the work in Corporate Quality Compliance, ensuring that we support the transformation of Orifarm so that Orifarm continues to be a customer-centered and healthy business as well as a great place to work. I look very much forward to collaborating with the competent team in Orifarm and supporting the exciting growth that lies ahead for Orifarm,” Birgitte Røddik says. Birgitte Røddik had her first day at Orifarm on 01 December 2023. She most recently held the position as Partner in consultant agency Valcon.

In November, Orifarm introduced Apovit food supplement at a pharmacy exhibition, attended by nearly 5,500 Finnish pharmacy workers.  The product lines launched are part of the Apovit Immune Boost effervescent tablet series. The Apovit Immune Boost products contain vitamin C and D, and the most popular flavors are made from real ginger and cranberry.  Previously exclusive to Denmark, Apovit's expansion into the Finnish market is a great milestone for Orifarm. We are very excited to introduce this beloved food supplement brand to a whole new audience.  A big thank you to everyone who played a role in making this launch a resounding success!  Read more about Apovit here: https://orifarmhealth.fi/tuotemerkit/apovit (In Finnish) https://www.apovit.dk/ (In Danish)

Orifarm is donating 4.5 tons of food supplements with short expiry dates to the Danish nonprofit organization Fødevarebanken.   Fødevarebanken fights food waste and food poverty in Denmark by distributing donated food to social organizations who provide care for people in need. “By collaborating with Fødevarebanken food supplements and vitamins that would otherwise be scrapped are put to good use – just as they were intended. The food supplements include products for pregnant women and babies, as well as multivitamins and omega-3 products. At Orifarm, we work to create healthy days for as many as possible. This collaboration is very close to our hearts and DNA,” says Lars Uglebjerg Olsen, Head of Global Innovation, OTC & Consumer Healthcare in Orifarm.  Today, Fødevarebanken collected 23 pallets of food supplements at Orifarm in Odense, Denmark, and we couldn’t be happier to see thousands of packets of great healthcare products being distributed to people in need. 

Closing our Viminco production site in Skælskør, Denmark, we've prioritized comprehensive support for impacted employees. While our outplacement efforts aimed to assist all, it became evident that the outplacement initiatives were not ideal for our colleagues aged 60 and above.  That’s why we're offering a unique opportunity to our colleagues aged 60 and above affected by the closure of the site in Skælskør.  Recognizing their imminent transition into retirement, we've extended a tailored package that allows them to convert various support elements—such as salary increments, stay-on bonuses, outplacement assistance, and educational support—into a prolonged employment period.  This approach allows for transitioning directly from active employment into retirement without the pressure of seeking new job opportunities.  "It is important for us that all of our employees are treated with care and respect, and we are committed to supporting colleagues at every stage of their career – from entry to exit. We experienced that a group of employees would not benefit from the support, so we decided to offer our affected employees aged 60 and above the option to convert the offered support into a longer employment period, allowing them to prolong their employments until their retirement," shares Camilla Risum Amjadi, HR Business Partner in Orifarm.  The employees will have their employment period prolonged, but will be placed on garden leave until the site closes.  Production activities at the Viminco site in Skælskør, Denmark, have ceased, moving operations to other Orifarm production sites in Denmark and Poland. 

The large Danish pharma company Orifarm, leading in parallel import in the EU, has appointed Andreas Friis as its new Chief People Officer. Andreas Friis joins Danish pharmaceutical company Orifarm as Chief People Officer. Having previously held positions in Novo Nordisk for 11 years, Andreas Friis joins Orifarm with experience from the industry, including from pharmaceutical manufacturing at the benefit of Orifarm, who in addition to its support and sales functions also comprise three manufacturing sites globally.  The appointment of Andreas Friis comes at a time when Orifarm following a large acquisition of more than 100 new brands from pharmaceutical company Takeda, and consequently onboarded more than 900 new employees, now looking to develop the people area further to support the overall further development of the company.   “In Orifarm we see our people as our most valuable asset. That is why it has been important to find the right fit, searching for a person who can support Orifarm’s growth journey and assist in developing our organization further. I am very pleased to welcome Andreas Friis to Orifarm. With Andreas, we welcome a highly skilled HR leader, who not only has vast experience from various areas within HR, but who also comes with experience from our industry,” says Erik Sandberg, CEO of Orifarm.  A task Andreas Friis looks forward to undertaking:  “I look very much forward to joining Orifarm, and to assisting in developing the business further. I believe in keeping things simple and dynamic, and I find Orifarm’s founders’ mindset of entrepreneurship and maneuverability as a good point of departure in doing so,” says Andreas Friis.  Andreas Friis has his first day at Orifarm on 01 December 2023. He recently held a position as Responsible for People & Organization in the large Danish food company Danish Crown.

As the largest life science company in Funen, we want to create an even stronger foothold for the industry in Funen, which is currently home to over 40 companies in the life science sector.   Therefore, we have joined forces with a number of other Funen life science companies in the association Life Science Funen, where Andreas Søderman, who is the head of Medical Affairs at Orifarm, is a member of the board.  Since our humble beginnings in 1994, Orifarm has grown rapidly and we now employ 2300 employees, of which about 700 work in Odense. To fulfill our ambition for continued growth, it is crucial to be able to attract strong competencies to our employee group.  “Our employees are our most important resource to be able to fulfill our ambitions for the future. Denmark generally has a strong position in pharma and the industry is in continued growth. We constantly need qualified employees. This applies of course to the health sector, but also within other areas such as IT and the commercial area. The joint collaboration in Life Science Funen can help to strengthen the overall life science ecosystem in Funen, thereby assisting in the development and attraction of strong competencies,” says Torsten Laen, Director, People Attraction & Development.  “The collaboration between public and private actors is important to be able to strengthen the life science area. With our location in Odense, we have a good starting point - we are centrally located and have a good collaboration with strong, local actors, including educational institutions and teaching hospitals,” says Torsten Laen.  You can read more about Life Science Funen in this article, in which Andreas Søderman elaborates on the need for competent candidates for the industry (In Danish). 

As one of Europe's major pharmaceutical importers, we are delighted to receive this recognition as part of the Healthcare and Pharmaceutical Awards 2023. Our goal is to make medicines more affordable and accessible to everyone.  To achieve this, we engage in parallel importing, a process where we import original pharmaceuticals from one country, repackage, relabel, and then sell them in another country. This allows us to offer these products at more affordable prices compared to the originals. Parallel imported medicine is the exact same as the original, but in a new package with information leaflets in the patients’ local language.  Through parallel import, we strive to enhance the accessibility and affordability of vital pharmaceuticals for the patients that need them, while also reducing the expense for the public healthcare systems.   We are happy to receive the Best Imported Pharmaceuticals Supplier in Europe 2023 award for our efforts, as recognized by the Global Health & Pharma Magazine in the UK. 

While it is common to meet pharmacists at your local pharmacy, they also play a key role in pharmaceutical companies like Orifarm. Pharmacists are experts in medicine and bring specialized knowledge to ensure the quality and compliance of pharmaceutical products. At Orifarm, pharmacists are appointed in various steps of our distribution process, ensuring that certificates, authorizations and other information is accurate. Pia Andkjær is a Regulatory Affairs Specialist at Orifarm, and as an educated pharmacist she brings relevant pharmaceutical knowledge to her role. Together with her team, Pia is responsible for submitting applications to the local authorities, ensuring that the our products meet the highest standards. Her knowledge and experience with working at a pharmacy brings valuable perspectives into her daily work at Orifarm: “Though being a pharmacist is not a requirement for working as a Regulatory Affairs Specialist, my pharmaceutical background ensures that I understand the content that I work with. Having worked at a pharmacy, I can also see things from the patients’ perspectives, which is crucial in our pursuit of creating healthy days for as many as possible,” says Regulatory Affairs Specialist Pia Andkjær.Pharmacists like Pia are imperative in our work as a pharmaceutical company, and we are proud to have them on our team.

Orifarm is one of the largest employers in the area around Łyszkowice, Poland, and is very closely tied to life in the local community. With our significant role, it is especially important to us that we are present and interact with the community around us. We always prioritize and enjoy inviting members of the community to learn more about Orifarm and the medicines we proudly provide to patients throughout Europe.    Yesterday, we had the pleasure of hosting a group of over 20 people from the municipality’s Senior Club, introducing them to Orifarm and giving a guided tour around our facilities. The group visited our production area, administration, and warehouse with great enthusiasm and listening very carefully through the entire tour.   The Łyszkowice manufacturing plant has been operating for several decades. In fact, 14 of the Senior Club’s 40 members are former employees at the plant, so for some the visit was also a joyous reunion. 

In a year of macroeconomic challenges and a focus on the continued transformation of Orifarm, the family-owned pharmaceutical company realizes increased revenue and improved operating results in 2022. Highlights from the 2022 accounts: Revenue increased by 7% to €1,513m, which is a new record for Orifarm.  Growth was driven by both business units, Health Access with 3% and Healthcare with 22%. Healthcare's growth, however, was positively affected by the fact that sales from acquired Takeda products only contributed to nine months of 2021 against all 12 months in 2022. Gross profit increased by 22% to a new record of €223.9m. The result for the year ended at €27.4m, which is lower than expected. This is due to one-off costs in connection with the closure of the Viminco factory in Skælskør, Denmark, as well as derived consequences of delivery issues, especially in the second half of 2022. Continued significant investments to strengthen Orifarm for future growth. Investments increased in 2022 by 35% to €26.2m, which brings the total investments in the past three fiscal years to around €65m. The number of employees increased by 9% to 2,136 employees compared to the previous year (average number of full-time employees). CEO Erik Sandberg, Orifarm Group A/S, comments on the result for 2022:  "We are once again increasing turnover with growth in both of our core businesses. Regrettably, our result after tax is unfortunately lower than expected. This is due to one-off costs in connection with closing our factory in Skælskør, Denmark, but unfortunately also the derived consequences of delivery problems. Externally, increased interest rates have also affected the result negatively.” In many ways, 2022 has been an unusual year for Orifarm, as the group has been focusing on completing the integration of over 110 products and two factories, which it took over in connection with the carve-out acquisition from Takeda in 2021. Orifarm completed the acquisition on 1 May 2022. "A carve-out acquisition is a huge exercise, which has also brought challenges for us. What frustrates me the most is that it has also brought about delivery problems, especially in the second half of 2022, with the problems it brings for customers and patients. We have put everything into getting it resolved, and I am happy to state that we are on the right track," says Erik Sandberg and at the same time sends his thanks to the employees. “I would like to extend my appreciation to all of our many dedicated colleagues for their great continued efforts in providing medicine to customers and patients, and at the same time taking part in the transformation of Orifarm,” says Erik Sandberg. Expectations for 2023  In 2023, Orifarm expects to continue the transformation of the business, as part of the execution of the company's growth strategy. "We are in a volatile time why it is difficult to predict the macroeconomic development, e.g., the interest rates, which necessitates that we remain agile and navigate in relation to the opportunities that arise. We continue to invest in building a more scalable business that enables us to integrate potential future acquisitions even better," says Erik Sandberg. 

Major acquisition and organic growth drive strongest ever performance Danish healthcare company, Orifarm, can celebrate an excellent result for 2021. Continued success in the parallel imports business and the EUR 615 million acquisition of 110 healthcare brands from Japanese Takeda, including the Danish brands Pamol and Kodimagnyl, have driven up operating profits by close to 40%. For the family-owned pharmaceutical company, 2021 was the sixth consecutive year of top-line growth. Turnover rose 27% to DKK 10,54 billion (EUR 1,417 billion). Operating profit reached DKK 412.8 million (EUR 55.5 mill.) – 39% up on the previous financial year, despite the impact of DKK 183 million (EUR 25 million) in non-recurring costs due to the Takeda integration. A year of challenges CEO Erik Sandberg calls the results especially impressive for a year characterised by sourcing and supply chain constraints and increased price competition: “It is amazing that, regardless of a major commercial Takeda product introduction last year involving many European countries, we delivered our best performance ever in our parallel import business. I am very proud of the effort of our 2,200 employees.” The 2021 annual report also includes nine months with former Takeda brands since Odense-based Orifarm acquired 110 Takeda healthcare brands, including generics, vitamins and minerals by April 1, 2021. Better access to healthcare According to Erik Sandberg, the more diverse product range gives the company a robustness and resilience that makes it better positioned to achieve its ambition – to make affordable, high-quality healthcare as widely accessible as possible. “Our one-stop-shop, with more than 5,000 pharmaceuticals, vitamins and minerals on our shelves, represents a strong combined offering to our customers, including pharmacies, consumers, hospitals and wholesalers. The Takeda integration has taken us to a new level of opportunities and is the latest chapter in Orifarm’s 27-year growth journey,” he says. In 2022, Orifarm expects revenue growth of 5% to 10% and operating profit growth in the 10% to 20% range, as the full effect of the newly acquired product portfolio kicks in.

Orifarm wants to be even more competitive in its 13 countries. For this reason, the Danish pharmaceutical company has, among other things, analyzed the possibilities for its production in Denmark. “We can succeed if we have a clear competitive advantage in scale, portfolio or unique capacities that together give our customers and patients the best opportunities . We have analyzed nine separate criteria, including CSR, quality, delivery reliability, cost, capacity, short- and long-term investment needs, production capacity and product portfolio. As a result of this review and in order to strengthen our product portfolio, maintain our competitiveness and deliver reliable supply, we have decided to transfer our products, manufactured in our Viminco site in Skælskør, Denmark, to our Hobro site, also in Denmark,” Erik Sandberg, CEO in Orifarm, says. Orifarm will now have one large production unit in Denmark instead of two small units. Orifarm also has production in Poland. “This means that we are expanding in Hobro, while we unfortunately will have to close our good production in Skælskør. The latter we will do during the next year and a half in a proper way in collaboration with the 130 skilled employees in Skælskør,” says Erik Sandberg. He underlines that it has been a very difficult decision because the managers and employees of Viminco have all done an excellent job for Orifarm for many years.

A large number of pharmaceutical companies from 23 countries in Europe are donating medical aid to Ukraine's needy people by means of the large Danish pharmaceutical company, Orifarm. This is organized through the non-profit organisation Affordable Medicines Europe, headquartered in Brussels, and the medical aid, which comprises many different products, contains everything from insulin and morphine to over-the-counter painkilling medicines.The CEO of Affordable Medicines Europe, Kasper Ernest, is very satisfied with the great support amongst the 100 member companies to donate medicine to Ukraine."We feel great support among the companies for this important, humanitarian effort, and it is a wide range of medical products that we are able to deliver already now. We are in contact with the Ukrainian health authorities about their needs, and the mayor of Gdansk has made sure that a number of Polish trucks will bring medicine to Ukraine from Orifarm's Czech facilities outside Prague,” Kasper Ernest says.He adds that the European Commission has also approved that Affordable Medicines Europe will have the option of sending medicines from companies in the UK to Ukraine via the Czech Republic.Orifarm, which is headquartered in Odense, Denmark, is going to receive all the medicine from the organization's member companies, and CEO in Orifarm, Erik Sandberg, is pleased that the company's Czech facility will be able to receive and distribute the many products fast."There is a great need for medicine in Ukraine, and it is important to help if you have the opportunity. We have a very efficient logistics center in the Czech Republic, where management and employees have immediately assumed the task of receiving the large amount of medicine soon coming in from many companies throughout Europe. From there it will be shipped to Ukraine as soon as possible. In addition, Orifarm will donate a large number of products ourselves to the Ukrainian people,” says Erik Sandberg.

Orifarm has established a broad system to ensure the best possible onboarding to its more than 900 new employees to make everyone feel as welcome as possible from the first time they enter Orifarm. In this way, Orifarm aims to create a mutual foundation and an even more united organisation among its now 2,200 employees in 13 countries.  The past year, Orifarm, the large pharmaceutical company from Funen, has welcomed more than 900 new employees. To integrate all into the Orifarm family, the number of introduction programs has increased. Birgitte Ladefoged, Chief Human Resources Officer, explains that Orifarm’s onboarding process helps to remain the corporate culture and the special Orifarm DNA. “It is a solid stepping stone when you join Orifarm as a new employee. Both employees, leaders and also the owners themselves, Birgitte and Hans Bøgh-Sørensen, prioritise our onboarding program,” Birgitte says and continues: “It is a huge strength that the Orifarm story continuously is being told by the owners.”Birgitte also mentions Orifarm’s feedback culture which definitely is observed in the onboarding process: “We ask for feedback after each general introduction programme and based on the comments, the programmes are regularly adjusted. With it, we challenge status quo,” she says. When a newcomer joins a department in Orifarm, one will be introduced to colleagues and relevant stakeholders. Parallel with the onboarding process within the department, the new employee will take part in the organisation’s formal onboarding process which consists of several elements. With a buddy program, a general introduction programme and a welcome session by Orifarm’s owners, Birgitte and Hans Bøgh-Sørensen, the company aims to onboard its new employees in the best possible way. Looking back on the onboarding in 2021, evaluations of Orifarm’s introduction programmes indicated how their newcomers truly value the effort that is put into welcoming all our new colleagues. Patrik Krog Christensen, S&OP Partner Trade, joined Orifarm in September, 2021, and has recently experienced the Orifarm’s onboarding process: Unluckily, at Patrik’s first day in Orifarm, he became stuck in a tailback. Even though he had left his home in Vejle in good time, he was half an hour late. However, his leader and colleagues was by no means bothered by his delay. He was met at the parking space and followed to the office where they welcomed him with breakfast. “From the beginning, the spirit was very warm and friendly. I felt very welcome,” Patrik says. Josefine Toftdal joined Orifarm in 2021 as a Sales Executive Assistant and she explains that she has never heard of such an intensive introduction programme before. Patrik agrees: “This onboarding is different to other onboarding processes I have experienced. You are not just thrown to the lions but instead, you are given the exact introduction you need to fulfil your job in the best possible way. It makes it unique.”

As student worker, Cecilie Hartvig Petersen receives a share of her employer’s profit. She works at Orifarm, one of Denmark’s largest healthcare companies. Clothes, textbooks and café visits.Students are familiar with these expenses. But bonus from the student job was not a well-known concept for one of the student workers at Orifarm, Cecilie Hartvig Petersen, when an extra-large amount appeared at her account this January.”This was a pleasant surprise. I was not aware of the bonus scheme, when I suddenly discovered a larger amount than my normal pay. It was a good recognition of my work, as I don’t take it for granted that companies include student workers in their bonus schemes,” says 24-year old Cecilie (in the photo), who ordinarily studies law at the University of Southern Denmark, SDU in Odense.She recently started on her master’s degree, and concurrently with her studies, she works in the legal department of Orifarm’s headquarters located in Odense. Here, she partly solves known tasks of contacting solicitors’ offices and managing document handling, and partly engages in tasks she has never handled previously. ”We enjoy a pleasant tone at work, and I feel that I am being treated on equal terms with the permanent employees,” says Cecilie. And that is precisely the core of how Orifarm regards employees.”This is our culture. Everyone is part of our results, and that is why we have a common profit sharing scheme. At Orifarm – as is also becoming a general trend - bonus is not based specifically on individual results but on the entire success of Orifarm,” explains CHRO, Birgitte Ladefoged. She emphasizes that a position as student worker is of great mutual value. ”The student workers – like interns and trainees – are a valuable part of the workforce at Orifarm. Through their professional competencies they infuse us with the newest knowledge and theory within their competencies, and they also contribute to creating an important diversity through their many and various educational affiliations as well as in terms of age. Our student workers develop into more attractive young people while staying with us, as they get to combine their theoretical knowledge with solid practical tasks, which makes them a stronger candidate when they have completed their studies. Often, we also see that they choose to stay with us afterwards,” the CHRO tells. Where Cecilie will choose to work two years from now, neither she nor Orifarm can tell at this point. ”I would like to work and live in another part of Denmark than here at Funen where I come from. But as Orifarm has an office in Copenhagen among others – and also offices in other countries than Denmark – the opportunities are many. This makes Orifarm interesting as a workplace.”

Orifarm’s deal with Takeda, a global biopharma headquartered in Japan, has been finalized. With this, Orifarm becomes Denmark’s biggest supplier of medicines measured by the number of packages sold to pharmacies. The Takeda deal includes two factories, 600 employees, as well as more than 110 medicines and dietary supplements changing hands in what is one of Denmark’s largest M&A transactions in years. This puts well-known brands into Danish hands, creating even more jobs in Denmark and providing new business opportunities for Orifarm. All while Orifarm is once again publishing the best results in company history. The transaction between Takeda and Orifarm of DKK 4.6 billion was first announced on 23 April 2020 pending regulatory approval, which has now been given. Orifarm is already Europe’s largest parallel importer of pharmaceuticals. The acquisition triples production and sales of over-the-counter and prescription generics. With this, Orifarm becomes Denmark’s biggest producer of over-the-counter medicines, as well as the biggest Danish supplier of medicines measured by the number of packages sold to pharmacies. “The deal is transformative for us. It provides added stability and gives us much more control over production lines,” says CEO Erik Sandberg, who is looking forward to welcoming the 600 new colleagues just after Easter. Well-known brands in Danish hands Among the 110 medicines and supplements Orifarm is acquiring are numerous well-known brands like Kodimagnyl, Pamol and Zymelin. “Originally, Kodimagnyl and Pamol were Danish-owned brands. Now they are coming home again, and when we buy them at the pharmacy and elsewhere, we know that these brands contribute to the creation of Danish jobs and tax revenue once again. I think that’s nice to know,” says Erik Sandberg. 150 new jobs in Denmark The purchase includes two very modern factories. One in Łyszkowice in Poland and one in Hobro including 600 employees, and more are needed. “We’re taking on production and sales employees. However, we lack personnel in all support positions that are not part of the acquisition. That in itself creates 150 new jobs,” says Erik Sandberg. Recruitment and employment are in full swing, just as the head office in Odense is being expanded by 14,000 m2, and a new office in Søborg north of Copenhagen has been opened as well. Historic deal for Orifarm For Orifarm’s founder, owner and chairman, Hans Bøgh-Sørensen, the deal is historic. “We future-proof Orifarm, cement our strong position in the Nordic market while expanding significantly in the northern European markets for generics. We expect a lot from Poland in particular, which is a new market for us,” says Hans Bøgh-Sørensen. Following the acquisition from Takeda, Orifarm now employs about 1,900 people, of whom roughly 450 are based at the head office in Odense. Best results Orifarm’s good results over the past several years have equipped the company for the big purchase. The completed deal coincides with the publishing of Orifarm’s 2020 accounts. The results are the best in the company’s history. Revenue has risen to EUR 1,115 million – up 14% from 2019. Earnings before tax excluding acquisition costs have increased to EUR 51.4 million, an increase of 12%. “In 2019, we delivered the best result in the company’s 25-year history. Now we have managed to beat the result in a very challenging year defined by Covid-19. This is due to the enormous and dedicated effort of all our employees. And this effort enables the company to grow continuously,” says Erik Sandberg.

With more than 1 billion EUR in turnover, the Odense based pharmaceutical company Orifarm can look back at 2020 as yet another record-breaking year. 2020 also marked the company’s 25th anniversary and included the company’s largest acquisition in history. In 2020, Orifarm's turnover increased 14% compared to 2019 and profit before tax excl. non-recurring items reached 51.4 million EUR, corresponding to a rise of 12% compared to the previous financial year. Orifarm’s growth for the fifth consecutive year is the result of a rise in sales of both parallel imported pharmaceuticals and generic pharmaceuticals. While sales of parallel imported pharmaceuticals constituted the largest share of the total turnover of 1,115 million EUR, sales of generic pharmaceuticals accounted for nearly 40% of the profit before tax in 2020. Orifarm’s CEO Erik Sandberg is pleased with the result and aware that it happens against a dark backdrop. “We cannot look back at 2020 without thinking about the COVID-19 virus, which hit many people, businesses, and societies hard. It is only thanks to the resilience, engagement, commitment, and flexibility of all of Orifarm’s employees that we  managed to continue our growth journey and to seize opportunities such as the acquisition of the Takeda assets. As a result of our combined efforts, we came out of 2020, where we also celebrated our 25th anniversary, stronger than ever”, says CEO Erik Sandberg. The year 2020 also marked the completion of the next step of the succession of Orifarm, where the owner of Orifarm Hans Bøgh-Sørensen transferred further shares to his three children Christian, Anne-Charlotte, and Andreas Bøgh-Sørensen to ensure that Orifarm will remain in the family’s ownership in future generations. Further, Hans Bøgh-Sørensen took over as Chairman of the Board of Directors. Further growth and a more balanced business portfolio Orifarm expects to achieve further organic growth within its two main business areas over the next years. In 2020, the business sold more than 28.3 million units of pharmaceuticals and healthcare products, representing an increase of 8.8% compared to 2019. Meanwhile, the acquisition of Takeda, including more than 100 products, two production facilities, and above 600 employees, will reinforce Orifarm’s position in key markets and expand its geographical reach to new markets. It will also lead to a more balanced business portfolio by making the parallel import of pharmaceuticals and the sales and production of prescription pharmaceuticals and over the counter (OTC) products equally important going forward. “In Orifarm’s 25 years of history, the owner family has always focused on creating a robust company. The acquisition of the Takeda assets is a real gamechanger for us, which will provide a larger portfolio of products and ensure a better balance between our business areas. As a result, we are in an even better position to handle future market fluctuations and unforeseen events such as COVID-19”, says CEO Erik Sandberg. Outlook for 2021 For 2021, Orifarm Group A/S expects revenue growth in the range of 10-15% and an operating profit growth in the range of 60-70%.

Orifarm Group, one of the leading pharmaceutical companies in the Nordic countries, has entered into an agreement to purchase a portfolio of select over-the-counter (OTC) and prescription pharmaceutical products sold in Europe from Takeda Pharmaceutical Company Limited for a purchase price of up to €615 million. Orifarm has acquired the rights for approximately 110 pharmaceuticals as well as 2 production sites. The acquisition is the largest in the company’s history and represents a key milestone in the company’s business strategy. The acquisition allows Orifarm to future-proof its business by strengthening the company’s  core business areas: parallel imported pharmaceuticals, over-the-counter pharmaceuticals, and prescription generic pharmaceuticals. The acquisition from Takeda will reinforce Orifarm’s position in its key markets and expand its geographic reach to exciting new markets, strengthening Orifarm’s position for the long-term from Orifarm’s heritage, where parallel import of pharmaceuticals has been the principle part of the company, the future sales and production of over-the-counter and prescription pharmaceuticals will become equally important. The products acquired from Takeda are a well-known and recognized portfolio across their key geographies, with significant brand recognition amongst pharmacists and consumers.  - Orifarm Group’s progress and record-breaking annual accounts in the recent years enables us to take this decisive step for the company’s future. It is a gigantic transaction for Orifarm and a game changer for Orifarm as a company. We will grow to a greater extent into a much more traditional manufacturing pharmaceutical company, and with the acquisition of both the line of products and two further manufacturing sites, we will be able to control a larger part of our value chain, says Erik Sandberg, CEO, Orifarm Group.    The record-breaking acquisition includes approximately 110 pharmaceuticals and dietary supplements, including well-known brands like Pamol, Kodimagnyl, and Zymelin.  It is anticipated that approximately 600 employees from the manufacturing sites, sales and marketing, and other select professionals supporting the portfolio and manufacturing sites, will transition to Orifarm at closing of the transaction.  The two highly modern manufacturing sites are based in Hobro, Denmark and Łyszkowice, Poland. Both sites produce a significant number of the pharmaceuticals, which Orifarm has acquired. The portfolio generated FY 2018 net sales of approximately €210 million.  The acquisition will future-proof Orifarm  Hans Bøgh-Sørensen, who is owner of Orifarm Group together with his family, considers the acquisition to be a giant step towards the long-time vision to build a company less exposed to fluctuations. -This transaction will always be a milestone in Orifarm’s history. During the company’s entire history we have focused on differentiation and development of the business from the beginning of Orifarm with parallel import in Denmark. At first, expansion to several countries, subsequently the business area of generic pharmaceuticals, and now the company will obtain its third business area with this large portfolio of over-the-counter pharmaceuticals, says Hans Bøgh-Sørensen, who is also Vice Chairman of Orifarm Group’s Board of Directors.  As the largest parallel importer of pharmaceuticals in Europe, parallel import represents 90% of Orifarm Group’s current turnover of close to €1 billion, but several acquisitions have now equalized this balance.   During summer 2019, Orifarm Group acquired the London-based company Pilatus, which added new business areas like comparator sourcing and unlicensed medicines. The acquisition of Pilatus also included a small division in the US which is expanding.  The large multi-million sized acquisition from Takeda will triple the production and sales of generic pharmaceuticals to approx. 25% of the total turnover with an expected increased part of the earnings as well. At the same time, Orifarm Group will become one of the largest producers of over-the-counter pharmaceuticals in the Nordic countries.   - The transaction has been in the pipeline for several months, and we now look forward to pushing forward to closing the acquisition and initiating the integration of the new employees and manufacturing sites to Orifarm’s existing organization, and to gain the full benefit of these new assets”, says Erik Sandberg, CEO, Orifarm Group.   The anticipated approximately 600 employees that will transition to Orifarm at closing of the transaction are divided between the manufacturing site in Hobro, Denmark, the manufacturing site in Łyszkowice, Poland, a sales force allocated to 8 different sales countries with large offices in Belgium and Poland, and other select professionals supporting the portfolio and manufacturing sites. After the acquisition from Takeda, Orifarm Group will employ around 1,800 employees, including close to 370 at the head office in Odense, Denmark.   The transaction is expected to close by the end of Takeda’s Fiscal Year 2020 (ending March 2021) subject to the satisfaction of customary closing conditions, receipt of required regulatory clearances and, where applicable, compliance with local works council requirements.  Orifarm is being advised by Danske Bank, Corporate Finance as our financial advisor and Kromann Reumert as our legal advisor in this transaction. Facts about Orifarm Group Orifarm Group is the largest parallel importer of pharmaceuticals in Europe and the largest supplier of pharmaceuticals in Denmark. The Group comprises a number of companies engaged in the import, production, re-packaging, distribution, registration, and sales of pharmaceuticals. The Group is engaged in parallel importing of pharmaceuticals from EU countries, which are sold in Denmark, Norway, Sweden, Finland, Germany, Holland, Austria, United Kingdom, and Belgium. Additionally, the Group is engaged in the sales of generic pharmaceuticals in the Nordic countries. A generic drug contains the same active ingredients as the original drug. The active ingredients are, however, no longer patented, and the generic drug can therefore be produced and sold at a lower price than the corresponding original. Orifarm Group is headquartered in Odense, Denmark, and employs approx. 1,200 employees until the acquisition from Takeda.

The Odense based pharmaceutical company Orifarm is presenting a new record-breaking annual report with the highest turnover and earnings in the company’s 25-year history.  In 2019, the turnover of the Orifarm Group reached MEUR 982. An 18% increase compared to the record-breaking year 2018. Profit before tax in 2019 reached MEUR 45.4 corresponding to a rise of 30% compared to the previous record from the financial year 2018.  The progress in 2019 is mainly attributable to a strong sales growth of parallel imported pharmaceuticals at the German market, which is also Orifarm’s largest market. Orifarm increased its market share and generated both higher turnover and earnings. Also generic pharmaceuticals showed progress where in particular the Norwegian market grew.  For Orifarm’s CEO Erik Sandberg the result is more than approved. - We have all worked hard and been careful not to rest on the laurels from last year’s result, and I am proud of the result we have achieved as a team. In addition to the awesome result we have also implemented a number of digitalization projects in our operation, which will make us even more competitive in the future. A future, of which we have high hopes.   Targets of continued growth  Orifarm Group has ambitions to continue the growth in the next few years. There is still a lot of potential within the two existing business areas, parallel imported pharmaceuticals and sale of generic pharmaceuticals. All in all, Orifarm has sold more than 26 million boxes of medicine in 2019. This entails another record for Orifarm.  In 2019, operating income increased by MEUR 7.8 to MEUR 48.1.  The parallel import business has not only increased the turnover in Germany, but also in Finland, Austria, and United Kingdom. However, the exchange rates in especially United Kingdom and Sweden have affected the earnings unfavorable.  The sale of generic pharmaceuticals in the Nordic countries has also been in clear progress in 2019, where turnover has increased with nearly 8%.  Acquisition – a part of the growth strategy Contemporary with the growth of the present business, Orifarm Group acquired the London based company Pilatus Comparator Solutions during summer 2019. Pilatus adds new business areas like comparator sourcing and unlicensed medicines to Orifarm Group.   - The acquisition of Pilatus is an example of the fact, that we keep a close eye on possible acquisitions which have synergies in terms of our present business areas. Pilatus has added some new activities, which we are about to develop and which we can infuse with a lot of muscle work with our comprehensive experience in parallel import, says Orifarm’s CEO Erik Sandberg.     Outlook for 2020 Orifarm Group’s target is a minor growth in revenue in 2020 and retention of earnings at 2019 level. 

For Orifarm, 2018 was a fantastic year. In fact, the best in the company's nearly 25-year history. Every day, the employees work hard to challenge the pharmaceutical market to provide cheaper pharmaceuticals to millions of consumers in Europe. And the employees do it well. In 2018, Orifarm Group sold more than 25 million products - or approx. 7% more products than in 2017, and this has resulted in record turnover and earnings. This week, Orifarm Group releases its 2018 Annual Report and the result beats all former company records. The Group's revenue increased by 4.7 % in 2018 to MEUR 833. Operating income excl. non-recurring items increased by MEUR 6.5 to MEUR 40.3, and earnings before tax increased to  record high MEUR 34.9. A very satisfactory result for the Group, which also exceeds the expectations. Erik Sandberg, who officially took over as CEO in January 2019, says: “In many ways, 2018 has been a fantastic year for us. A year where we have met lots of challenges in the markets, and where we have been through a major reorganization internally. Nevertheless, we have succeeded in creating great results for the Group together. It proves our willingness and ability to make a difference - for consumers, society and the company. All employees can be proud of what we achieved together in 2018, as it would not have happened without them.” More consumers have bought Orifarm's products The Group's financial growth was especially generated in the parallel import business, which repackages and sells pharmaceutical products within the EU / EEA. The parallel import business sold 11 % more products in 2018 compared to 2017, which led to growth in both revenue and earnings in 2018. The 2018 revenue from parallel imported products totalled MEUR 756. This is an increase of 4.9 % compared to 2017. The result of main activities excl. non-recurring items increased by MEUR 8.0 to MEUR 34.2. In spite of intense competition in 2018, Orifarm succeeded in generating great results in Germany, which is the Group's largest market, as well as in Denmark, the Netherlands and Austria. In Sweden, the Group's earnings has been under pressure due to the Swedish currency exchange rate, but Orifarm maintained its position at the Swedish market. The parallel import business sold more products in the UK in 2018 compared to the previous year, but the weak British currency puts pressure on the profit. The Group's other business area, the generic pharmaceuticals, had a difficult year with stagnation in revenue and decreasing income. Nevertheless, the generic pharmaceuticals sold 4 % more products in 2018 compared to the year before. Challenging market conditions and challenges in maintaining a stable supply of few, and normally well performing products, put pressure on the Group's revenue and earnings from the generic products. Operating income fell by MEUR 2.6 to MEUR 9.7, however, it was possible to maintain revenue at the same level as in 2017 (MEUR 9.7). “We have done well in 2018 in difficult conditions, and we have the ambition and the belief in being able to continue growth and a positive development for Orifarm. But we are also realistic and 2019 will be at least as challenging as 2018, characterized by strong competition at all Orifarm's markets. But we have so many skilled employees who drive Orifarm forward. Therefore, I am confident that together we can meet the common goals for 2019,” says Erik Sandberg, CEO at Orifarm Group.

Orifarm Group manages to provide cheaper pharmaceuticals to millions of consumers in Europe while earning money to invest in future activities. Despite fierce competition, Orifarm closes its fiscal year 2017 with an annual result showing 10 percent growth in net turnover and the second best earnings in the history of the company. This week Orifarm Group presents the financial statement of 2017 and the Danish-owned pharmaceutical company continues to do well. The Group's net turnover increased by 10 percent to EUR 797 million in 2017, the result of main activities rose to EUR 34 million and the result before tax increased to EUR 29 million. Lower priced parallel imported products are the main driverThe improved Orifarm Group results are in particular due to the parallel import business handled by Orifarm Parallel Import. The business division showed a positive development and reasonable results throughout mature as well as new markets. Orifarm Parallel Import, which repackages and sells pharmaceuticals within the EU - and constitutes the largest of the two business areas - accounts for a net turnover of EUR 720 million. This is an increase in net turnover of 11 percent when compared to 2016. Results of main activities excl. non-recurring items rose by EUR 4.2 million to EUR 26.2 million. Generic products, which are the Group's second business area and handled by Orifarm Generics, completed 2017 with a slight decline in net turnover as well as earnings. Net turnover for 2017 ended at EUR 77 million, which represents a decrease of EUR 2 million when compared to 2016. Results of main activities excl. non-recurring items decreased by EUR 2 million to EUR 12.3 million. The 2017 results follow several years of strong growth in Orifarm Generics, and Orifarm Group is now investing significantly to ensure future growth in the business area. President and CEO Hans Bøgh-Sørensen is very satisfied with the 2017 Group result: "In 2017, the parallel import business has performed very well. It is an area of fierce competition among many companies. Consequently, it requires a dedicated and focused organization with ambitious employees who understand how to make a good deal on behalf of society, consumers and Orifarm”, he says, continuing: "our mission is to challenge the pharmaceutical market to ensure a ‘better deal’ for all and, of course, I am happy to see when we succeed in doing this." Especially Germany, Orifarm's largest single market for parallel imported products, has contributed significantly to the excellent result, despite the intense competition and the same applies to Denmark. Orifarm is also successful in gaining ground in the new markets. In particular, the Netherlands and Austria contributed positively to the results in 2017. Orifarm Group invests further in generic products After several years of great success and significant growth within generic products, 2017 became a more even year for Orifarm Generics. Orifarm Generics performed well during the first half of 2017 in Denmark and Sweden, but faced fierce price competition in the second half of 2017 in both countries. However, the management of Orifarm Group remains fully confident that the generic business also has an important role to play in the future. Hans Bøgh-Sørensen elaborates: "We are convinced that also in the future we can make a big difference for consumers within generics - both in Denmark and in other markets as well. Therefore, the Group is investing heavily in Orifarm Generics' future growth, for instance in an extension of the laboratory at the location in Skælskør, Denmark. In Skælskør, employees work hard to develop new products, which we then produce and sell at favorable prices." The location in Skælskør houses Viminco, which employs approximately 100 employees. Orifarm Group acquired Viminco in 2015 as part of an increased strategic focus on retail medicine and niche products. Synergies support future growth Orifarm is an ambitious company that strives to achieve even better results. In order to ensure the right foundation for future growth, Orifarm has just begun restructuring the company. Hans Bøgh-Sørensen says: “We see many changes in Orifarm´s environment these years and our business is developing rapidly. As responsible managers, we must always ensure that the company and the employees are well equipped to meet the challenges of the future. Therefore, we have just decided to break down the silos internally and merge the two business areas to a higher degree than we have had so far. In this way, we expect to benefit from the many synergies that exist across the two business areas, thus creating a solid foundation for further growth in the Group."Orifarm Group expects activity and results for 2018 to be at same level as 2017.

Danish pharmaceutical company Orifarm delivered solid results in 2024, achieving 16% revenue growth and the highest turnover in the company’s history. Despite robust commercial performance, higher operational costs resulted in a decline in operating profit. To lead the business through the next phase of its growth journey, Orifarm has announced the search for a new CEO. Orifarm delivered solid results in 2024, generating robust commercial performance and improving cash flow. Revenue grew 16% reaching a record €1.816bn, fuelled primarily by 19% growth in the Pharma Trade segment and 9% growth in Specialty Rx. Additionally, free cash flow improved to €40.6m (2023: -€10.5m), driven by stronger working capital management. In 2024, Orifarm reinforced its financial position through a new financing partnership with Carlyle and the refinancing of senior facilities with Danske Bank, Nykredit, and Jyske Bank. However, higher operating costs resulted in an operating profit of €69.4m, a 9% decline from the previous year. To address this, Orifarm has taken steps to build a scalable organisation positioned for sustainable growth. These measures included workforce adjustments at the beginning of 2025 and plans to nearshore up to approximately 140 positions to Warsaw, Poland by the end of 2026. "Orifarm is pleased with our record revenue growth and cash flow improvements thanks to the continuous dedication from our employees. To fulfil our long-term growth ambitions, we also need to build a more scalable organisation and control costs. As we continue expanding our portfolio and global footprint, our focus in 2025 will be on improving profitability, so we can provide affordable high-quality medicine to even more consumers across Europe," says Mads Fink Eriksen, CFO at Orifarm. This year, the company anticipates 5% revenue growth and aims to increase operating profit by 5–10%. Orifarm’s strategic priorities for 2025 include plans to enter the Spanish market, launch speciality Rx in Germany and continue to pursue merger and acquisitions.   Orifarm to find new CEO To lead the company in the next phase of its growth journey, Orifarm’s Board of Directors has decided to find a new CEO. The Board would like to express its gratitude to Erik Sandberg, who steps down as CEO with immediate effect. Orifarm’s CFO Mads Fink Eriksen will act as interim CEO until a new CEO is appointed. Commenting on the decision, Hans Bøgh-Sørensen, Owner and Chairman of the Board, says: “Orifarm’s Board of Directors has decided to find a new CEO to guide the company through the next stage of its growth journey. We would like to thank Erik Sandberg for his substantial and loyal contribution to Orifarm over the past 13 years, in which he has significantly strengthened the company’s position by expanding the company’s portfolio and global footprint. The Board will now start the search for a new CEO and during this time Mads Fink Eriksen will act as interim CEO.” Erik Sandberg says: “It has been a privilege to lead Orifarm. I am proud to have led the company through a strategic transformation over the past 13 years and would like to thank Orifarm’s employees for their dedication and support. I respect the Board’s decision to find a new CEO for the next part of Orifarm’s journey and look forward to seeing the company continuing to grow in the future.” In addition to the CEO leadership changes announced today, the Board has appointed Thomas Brandhof, Chief Commercial Officer at Orifarm, to join Mads Fink Eriksen on the executive board. 2024 financial highlights  Revenue grew 16% reaching €1.816bn, the highest turnover in the company’s history.  Product portfolio delivered strong commercial performance fuelled by 19% growth in the Pharma Trade segment and 9% growth in Specialty Rx. Higher operating costs resulted in an operating profit of €69.4m, a 9% decline from the previous year. Cash flow improved to €40.6m (2023: -€10.5m), driven by stronger working capital management.

Orifarm announced today the appointment of Mads Fink Eriksen as CEO with immediate effect. Mads, who has been serving as CFO and interim CEO, is poised to propel the company forward on its growth trajectory by expanding its commercial platform and delivering sustainable, profitable growth.   The appointment by the Board of Directors follows a comprehensive search process with support from international advisers and a detailed evaluation of internal and external candidates.   Hans Bøgh-Sørensen, Owner and Chairman of the Board, said: “The Board is delighted to appoint Mads Fink Eriksen as Orifarm’s new CEO. Having undertaken a thorough screening process involving high-caliber candidates, the Board unanimously agrees that Mads is the right leader for Orifarm. His strong leadership qualities, proven ability to execute and embodiment of Orifarm’s values make Mads the right match to steer Orifarm on the next phase of our growth journey. We look forward to working with Mads as we move towards an even stronger future.”  Mads brings many years of leadership in growing international companies, latterly from the family-owned company ECCO. His experience spans the entire value chain, with roles in production, sales, and corporate functions. Throughout his career, his strong business acumen and leadership skills have consistently driven solid financial results and strategic transformation. As CEO, Mads will focus on continuing Orifarm’s strong growth journey by expanding the company’s commercial platform and delivering sustainable growth. Mads Fink Eriksen expressed his commitment to the role: “I am honored to lead Orifarm – an ambitious company with great people. To realize our many opportunities ahead, our focus remains on strengthening our foundation for sustainable, profitable growth. As we continue expanding our portfolio and global footprint, my task is to improve profitability, build a more scalable organization and execute on our strategic priorities. Together with the executive management group and the Board, I look forward to building on Orifarm’s impressive legacy so we can provide access to high-quality, affordable medicine to even more customers in the future.” Mads joined Orifarm in October last year and has been interim CEO since the end of March. Orifarm will now start the search for a new CFO.   About Mads Fink Eriksen Before joining Orifarm, Mads Fink Eriksen spent 14 years with ECCO, starting in China, followed by several years in Singapore in ECCO’s Global Production Headquarter. He then spent three years at ECCO’s headquarters in Denmark as Head of Corporate Finance. In 2018, he moved to Australia, where he successfully restructured ECCO’s sales organization in Oceania. In 2020, he was appointed Chief Financial Officer for the ECCO Group. Mads holds an Executive MBA from the renowned INSEAD Business School. Mads, 42, is married with two children. 

Thirty years ago, a couple and their dog sat in an office in Odense. They had a filing cabinet, an idea, and an ambition: to make medicine a better deal—not just for themselves, but also for patients and society. This vision sparked a remarkable growth journey, where acquisitions and sales transformed the idea into a European leader in parallel import. Today, Orifarm celebrates its 30th anniversary, and the couple behind this Danish business success story express their gratitude to employees and partners for their support throughout the journey.  On Thursday, May 22, 2025, Orifarm marks its 30th anniversary and an extraordinary growth journey that has made the family-owned Danish company the largest supplier of medicine to Danish pharmacies and Europe’s largest parallel importer of pharmaceuticals.  Behind this journey stands the couple Birgitte and Hans Bøgh-Sørensen, who are still active in the company’s leadership. For the first time, with input from employees and partners, they tell Orifarm’s complete story in the book “Success on Prescription”, published today by Politikens Forlag.  From filing cabinet to multi-billion enterprise Orifarm was founded on the principle of parallel import—buying original medicine at a lower price in one EU country and selling it at a lower cost than the original producer in another.  “We started Orifarm with an idea and a filing cabinet we bought, containing a few documents about products and suppliers. Today, we have an international company and around 2,300 colleagues. We never imagined this back then,” says Hans Bøgh-Sørensen, founder, co-owner, and Chairman of the Board.  An idea with social impact Since then, Orifarm has expanded its business with generic medicine, over-the-counter drugs, vitamins, and dietary supplements — always with a focus on providing cheaper, high-quality pharmaceuticals.  Parallel import alone saved Denmark 740 million DKK in 2021, according to a report by Copenhagen Economics in 20221. Additional savings stem from the generic medicine market, where competition among suppliers has led to lower prices2.  “It’s not just about running a good business—it’s about making a difference. We have always been driven by the desire to create value for both patients and society,” says Hans Bøgh-Sørensen.  A value-based growth company  Orifarm has experienced continuous growth over the years — but not without challenges. Legal hurdles, Brexit, regulatory changes, and other obstacles have caused difficulties but have also often served as a driving force. The company has carried out several strategic acquisitions, most recently acquiring 110 products and two production facilities from the Japanese pharmaceutical giant Takeda in 2020 — Orifarm’s largest and most complex acquisition to date.  “We have never been afraid to think big. But we’ve always put our values first and built on a strong culture. It’s important that we can see ourselves in what we do — even as we grow. Our culture and values are our compass,” says Birgitte Bøgh-Sørensen.  A family-owned business focused on long-term growth Orifarm remains 100% family-owned. Today, the company is owned by the couple’s three adult children — Christian, Anne-Charlotte, and Andreas — who each own 30%. Hans Bøgh-Sørensen holds the remaining 10% and the controlling shares, ensuring continuity as the next generation prepares to carry forward what their parents built.  “But Orifarm is not just our story — it has been created by many. We owe a deep gratitude to everyone who has been part of it — whether in administration, production, or behind the scenes. We are incredibly thankful to them,” says Hans Bøgh-Sørensen.  Orifarm achieved record revenue of approximately 13.5 billion DKK last year (2024) and now poised for a new growth phase, aiming to significantly expand its business establish itself as a mid-sized European pharmaceutical leader, starting in Northern Europe and expanding across the continent. “We have Europe’s strongest position in parallel import and a solid foundation in generic medicine. Now, we want to use this as a springboard for something even bigger. Our ambitions remain unchanged — we are just getting started,” says Hans Bøgh-Sørensen.          ------------------------------ Book release: On Thursday, May 22, 2025, the book Success on Prescription – The Story of Orifarm will be published by Politikens Forlag. Released in celebration of Orifarm’s 30th anniversary, the book is written by journalist Tom Okke. Based on interviews with Birgitte and Hans Bøgh-Sørensen, along with more than 20 former and current employees and partners, the author portrays the company's transformation over the past 30 years.  Sources:  1.    Copenhagen Economics: The Impact of Parallel Imported Medicine (Copenhagen Economics: Effekten af parallel importeret medicin)2.    IGL: Societal Savings from Generic Medicines (IGL: Besparelser til samfundet med generika) Image material: Portrait photo of Birgitte and Hans Bøgh-Sørensen. Photographer must be credited when used: Jens Peter Engedal.  

Orifarm announces two new appointments to its Executive Management Group, effective today. Kenneth Svendsen joins as new Chief Information Officer (CIO) and Nicki Lund Kristensen is appointed new Chief Financial Officer (CFO). The move strengthens the executive leadership team, and will support Orifarm in delivering profitable growth and executing on its strategic priorities. “I am excited to welcome Kenneth Svendsen and Nicki Lund Kristensen to Orifarm’s Executive Management Group today. These appointments will play a key role in securing profitable growth, executing on our strategic priorities – delivering on our mission to provide affordable, high-quality healthcare to even more patients, customers and societies across our markets,” says Mads Fink Eriksen, CEO at Orifarm. New CIO to spearhead tech journey   Kenneth Svendsen is an experienced international IT leader with a strong track record in leading digital, business-driven transformations. With his strong focus on supporting strategic development and optimizing IT operations, Kenneth Svendsen will be responsible for building technology resilience and capabilities that deliver value across the business. The appointment marks the expansion of Orifarm’s Executive Management Group. “I’m excited to join Orifarm’s executive management at a time of such momentum. Technology is at the heart of Orifarm’s growth journey, shaping everything from operations to strategy. I look forward to accelerating this journey by harnessing the potential of technologies and AI across our value chain. By supporting our strategic priorities, optimizing operations and making future-proof tech investments, I will be strongly focused on driving value in all parts of the business,” says Kenneth Svendsen, CIO at Orifarm. Kenneth Svendsen has held several international leadership positions, most recently CIO at Dagrofa. Prior to this Kenneth Svendsen was Division CIO at DSV, Group CIO at FLSmidth and CTO at Saint-Gobain General Delegation Nordic & Baltic. He holds a bachelor in Computer Science from Niels Brock Copenhagen Business College. Kenneth Svendsen is 51 years old, married and has three children. New CFO to continue growth trajectory As Orifarm’s new CFO, Nicki Lund Kristensen will play an even more instrumental role in steering Orifarm on its growth trajectory. Nicki Lund Kristensen has been at Orifarm for more than four years, and has played a key role in financial management in his previous position as Vice President Group Accounting, Compliance and Treasury. His appointment marks the completion of a comprehensive internal and external search following the appointment of Mads Fink Eriksen as CEO. “My primary objective is to build on the strong foundation already in place, made possible by the continued dedication of our employees. Orifarm is delivering robust commercial performance, and as we pursue our long-term growth ambitions, our focus remains on increasing profitability, enhancing scalability, and creating value across the whole value chain,” says Nicki Lund Kristensen, CFO at Orifarm. Prior to joining Orifarm, Nicki Lund Kristensen held various leadership roles at Blue Water Shipping including Head of Treasury. He holds a Graduate Diploma in Business Administration (Financial and Management Accounting) from the University of Southern Denmark. The 42-year-old lives in Esbjerg and is the proud parent of two children.   Nicki Lund Kristensen (left) and Kenneth Svendsen (right)